香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立正 達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《2025年年度報告摘要》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年3月31日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；本公 司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市春立正达医疗器械股份有限公司202 ...

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Chunli Medical (01858.HK) by 168,200 shares on February 27, with a total net increase of 152,000 shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have reduced their holdings in Chunli Medical for 12 days, resulting in a cumulative net reduction of 1,129,700 shares [1] - As of now, southbound funds hold 41,216,800 shares of Chunli Medical, accounting for 43.31% of the company's total issued ordinary shares [1] Group 2 - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices in China [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - The joint prosthetics product line covers four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Southbound funds have reduced their holdings in Spring Medical (01858.HK) by 31,000 shares on February 10, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings on 4 days, with a total net reduction of 789,500 shares [1] - Over the past 20 trading days, there have been 11 days of net selling, resulting in a cumulative net reduction of 901,200 shares [1] - Currently, southbound funds hold 41,446,300 shares of Spring Medical, accounting for 43.55% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover major human joints such as hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 153,800 shares on February 5, 2026, marking a decrease of 0.37% [1][2] - Over the past five trading days, there have been three days of net reductions by southbound funds, totaling 427,300 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 2,033,000 shares [1] Group 2 - As of now, southbound funds hold 41,678,300 shares of Spring Medical, which represents 43.79% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as the hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [2]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a net reduction in holdings over the past trading days [1] - On February 2, 2026, southbound funds increased their holdings by 74,000 shares, marking a 0.18% increase [2] - Over the last five trading days, there were four days of net reductions, totaling a decrease of 405,800 shares [1][2] - In the last 20 trading days, there were 11 days of net reductions, with a cumulative decrease of 3,113,500 shares [1] Group 2 - As of February 2, 2026, southbound funds hold a total of 42,151,300 shares of Spring Medical, which represents 44.29% of the company's issued ordinary shares [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and are sold in both domestic and international markets [2]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook for participation in the upcoming stock issuance [22]. Core Insights - The company is a high-quality orthopedic consumables provider, established in 2015, with a focus on spinal, trauma, and sports medicine products. It ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant devices as of 2023 [3][7]. - The company has a competitive advantage in core technologies, with a total of 108 patents, including 41 invention patents, and has established a nationwide sales network [3][7]. - Revenue for 2024 is projected at 275 million yuan, with a slight decline over the past three years at a CAGR of -1.9%. However, non-collection products are expected to grow rapidly, potentially becoming a new growth driver [8][22]. - The company plans to use the raised funds primarily for expanding production capacity in orthopedic consumables, as well as for building a research and development center and marketing network [9][22]. Summary by Sections 1. Company Overview - The company specializes in orthopedic consumables and aims to provide comprehensive solutions for orthopedic surgeries. It has a diverse product matrix and a strong focus on R&D and customer service [3][7]. 2. Issuance Plan - The new stock issuance will adopt a direct pricing method, with an issue price of 7.67 yuan per share. The initial issuance scale is 29.53 million shares, accounting for 25% of the total post-issue share capital, with an expected market capitalization of 906 million yuan [12][13]. 3. Industry Situation - The aging population is driving an increase in the incidence of orthopedic diseases. The proportion of the population aged 65 and above reached 15.64% in 2022, up 5.17% from 2015. This demographic shift is expected to increase the demand for orthopedic products [16][14]. 4. Competitive Advantages - The company has developed a comprehensive product matrix that covers various orthopedic clinical indications. It has established a robust sales network across all provinces in China, enhancing its market presence and customer relationships [17][3]. 5. Comparable Companies - The company’s financial metrics, including a projected gross margin of 58.05% for 2024, are competitive compared to peers in the industry. The average PE ratio of comparable companies is 60, while the company’s PE ratio is significantly lower at 11.65 [21][23]. 6. Subscription Analysis - The company is positioned as a leading player in the medical dressing market, with strong competitive advantages in various segments. The current production capacity is highly utilized, and the planned expansion is expected to unlock growth potential [22].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Chunli Medical (01858.HK) by 385,200 shares on January 29, with a total net reduction of 241,000 shares over the last five trading days and 3,009,300 shares over the last twenty trading days [1] - As of now, southbound funds hold 42,105,600 shares of Chunli Medical, accounting for 44.25% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] Group 2 - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

Core Insights - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 21,200 shares on January 23 [1] - Over the past five trading days, there have been five days of net increases in holdings, totaling 995,300 shares [1] - In the last twenty trading days, there were eight days of net reductions, amounting to 2,141,500 shares [1] - Currently, southbound funds hold 42,367,800 shares of Chuangli Medical, representing 44.52% of the company's issued ordinary shares [1] Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow [1] - The company's products are sold in both domestic and international markets [1]